Soluble Epoxide Hydrolase Inhibitors Reduce the Development of Atherosclerosis in Apolipoprotein E-Knockout Mouse Model
- 1 October 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Cardiovascular Pharmacology
- Vol. 52 (4), 314-323
- https://doi.org/10.1097/fjc.0b013e318185fa3c
Abstract
To determine whether sEH inhibitors influence atherosclerotic lesion formation, we used an established murine model of accelerated atherogenesis, ApoE knockout (-/-) mice. The sEH inhibitor, 1-adamantan-3-(5-(2-(2-ethylethoxy)ethoxy)pentyl)urea (AEPU) was delivered in drinking water. All animals were fed an atherogenic diet while simultaneously infused with angiotensin II by osmotic minipump to induce atherosclerosis. In AEPU-treated animals, there was a 53% reduction in atherosclerotic lesions in the descending aortae as compared to control aortae. AEPU and its major metabolites were detected in the plasma of animals which received it. As expected from the inhibition of sEH, a significant increase in linoleic and arachidonic acid epoxides, as well as an increase in individual 11,12-EET/DHET and 14,15-EET/DHET ratios, were observed. The reduction in atherosclerotic lesion area was inversely correlated with 11,12- and 14,15- EET/DHET ratios, suggesting that the reduction corresponds to the inhibition of sEH. Our data suggest that orally-available sEH inhibitors may be useful in the treatment of patients with atherosclerotic cardiovascular disease.Keywords
This publication has 36 references indexed in Scilit:
- Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk PredictionClinical Chemistry, 2008
- Effects of human soluble epoxide hydrolase polymorphisms on isoprenoid phosphate hydrolysisBiochemical and Biophysical Research Communications, 2006
- Review article: hyperlipidaemia and cardiovascular riskAlimentary Pharmacology & Therapeutics, 2005
- An Orally Active Epoxide Hydrolase Inhibitor Lowers Blood Pressure and Provides Renal Protection in Salt-Sensitive HypertensionHypertension, 2005
- Soluble epoxide hydrolase is a therapeutic target for acute inflammationProceedings of the National Academy of Sciences of the United States of America, 2005
- Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studiesAnalytical Biochemistry, 2005
- Effects of Topiramate on Ethanol and Saccharin Consumption and Preferences in C57BL/6J MiceAlcohol: Clinical and Experimental Research, 2005
- Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice.Circulation, 2001
- Analysis of the Cytotoxic Properties of Linoleic Acid Metabolites Produced by Renal and Hepatic P450sToxicology and Applied Pharmacology, 2000
- Chronic Angiotensin II Infusion Promotes Atherogenesis in Low Density Lipoprotein Receptor −/− MiceAnnals of the New York Academy of Sciences, 1999